Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NUL7
UPID:
DDX28_HUMAN
Alternative names:
Mitochondrial DEAD box protein 28
Alternative UPACC:
Q9NUL7
Background:
The Probable ATP-dependent RNA helicase DDX28, also known as Mitochondrial DEAD box protein 28, is pivotal in mitochondrial ribosomal assembly. Its helicase activity, crucial for this process, is supported by RNA and Mg(2+)-dependent ATPase activity. This protein's involvement in RNA processing or transport further underscores its essential role in cellular function.
Therapeutic significance:
Understanding the role of Probable ATP-dependent RNA helicase DDX28 could open doors to potential therapeutic strategies.